Novel therapeutic approaches targeting endotypes of severe airway disease

Filippo, Maria De; Votto, Martina; Licari, Amelia; Pagella, Fabio; Benazzo, Marco; Ciprandi, Giorgio

doi:10.1080/17476348.2021.1937132

Cited by 9 publications

(4 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large number of studies have attempted to identify patient variables that drive CRS patterns and response to treatment ( Jurlin et al., 2019 ; Morse et al., 2019 ; De Filippo et al., 2021 ; Soler et al., 2021 ). However, limited evidence suggests that advanced age can result in a unique CRS pathophysiology and potentially influences response to medical therapy.…”

Section: Discussionmentioning

confidence: 99%

Age-Associated Changes of Nasal Bacterial Microbiome in Patients With Chronic Rhinosinusitis

Chen

Gao

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Age-related changes in nasal bacterial microbiota of patients with chronic rhinosinusitis (CRS) remains unclear. In this study, we aimed to identify distinct characteristics of nasal bacterial microbiota between aged and younger patients with CRS through 16S rDNA gene sequencing. Patients with CRS undergoing endoscopic sinus surgery were recruited and separated into aged (≥60 years, median age = 66 years, N = 17) and younger (<60 years, median age = 35.5 years, N = 14) patients. Diversity, bacterial composition and metabolic activities of nasal microbiota between aged and younger patients were compared. Results have shown that levels of OTUs (p = 0.0173) and microbiota diversity (all p < 0.05) decreased significantly in aged patients. The abundance of phylum Actinobacteria, and genus Corynebacterium were significantly higher in aged patients, while the abundance of phylum Bacteroidetes, Fusobacteria, and genus Fusobacterium, Peptoniphilus were significantly higher in younger patients. In addition, predicted functional profiles have revealed that 41 KEGG pathways involving in 12 metabolic pathways, 4 genetic information processing, 3 environmental information processing, 4 cellular processes, 8 organismal systems, 6 human diseases, and 4 unclassified pathways were identified. Among which, the vast majority of metabolic activities are involved in replication and repair, membrane transport, translation, and the metabolism of amino acid, carbohydrate, energy, cofactors and vitamins, and nucleotide. On the level of the thirdly bacterial metabolic pathways, purine metabolism, glycine, serine and threonine metabolism, valine, leucine and isoleucine biosynthesis, glycolysis/gluconeogenesis and phenylalanine, tyrosine and tryptophan biosynthesis are significantly up-regulated while carbon fixation pathways in prokaryotesand methane metabolism are significantly down-regulated in aged patients. Overall, our analysis revealed that age-related physiological and pathological changes on the nasal mucosal surface may alter the host immune response and be highly associated with the nasal bacterial microbiota of patients with CRS. However, future studies are needed to elucidate the causal relationship.

show abstract

Section: Discussionmentioning

confidence: 99%

Age-Associated Changes of Nasal Bacterial Microbiome in Patients With Chronic Rhinosinusitis

Chen

Gao

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…This therapy was also approved and registered in 2014 to treat chronic spontaneous urticaria, with or without angioedema, for patients older than 12 years. [14][15][16][17] Omalizumab is the most commonly prescribed biological drug worldwide due to its efficacy and good safety profile. 18 Omalizumab neutralizes circulating IgE and reduces the high-affinity IgE receptor (FcεR) expression on the surface of mast cells, basophils, eosinophils, and neutrophils, thereby inhibiting the release of inflammatory mediators.…”

Section: Omalizumabmentioning

confidence: 99%

“…More recent studies have highlighted the possible role of omalizumab in reducing the expression of bronchial tissue remodeling mediators. [12][13][14][15][16][17] Finally, long-term studies have shown that omalizumab persistently reduces IgE production, even after discontinuing therapy. 19…”

Section: Omalizumabmentioning

confidence: 99%

Omalizumab and allergen immunotherapy for respiratory allergies

Filippo

Votto

Caminiti

et al. 2022

Allergol Immunopathol

View full text Add to dashboard Cite

Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.

show abstract

“…In the last decade, a new promising direction has appeared in the treatment of asthma -targeted therapy with humanized monoclonal antibodies (biologics) [14], [15].…”

Section: Introductionmentioning

confidence: 99%

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Бойко¹,

Stagnieva²,

Lodochkina³

2023

SEE J Immunol

View full text Add to dashboard Cite

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are comorbid, mutually burdening, difficult-to-treat diseases. The presence of a correlation between the severity of the course of CRSwNP and eosinophilic asthma, the proximity of the endotypes of these diseases, and the success in the application of humanized monoclonal antibodies for the treatment of severe asthma explain the interest in the study of the possibility of using this group of medications in patients with CRSwNP. AIM: The present study purposes to evaluate changes in the severity of CRS symptoms in patients with comorbid asthma during reslizumab treatment. The clinical effect of the treatment, the dynamics of subjective and objective characteristics of (CRSwNP) and asthma symptoms, indicators of general and local eosinophilia have been analyzed. MATERIALS AND METHODS: The study involved 18 patients with severe eosinophilic asthma, treated with reslizumab. Research protocol: the first examination conducted before reslizumab treatment included an assessment of clinical symptoms using Sino-nasal outcome test-22 and asthma control test, endoscopic examination of the nasal cavity, computed tomography of the paranasal sinuses, rhinocytogram, determination of the content of eosinophils and eosinophil cation protein in the blood, spirometry. Evaluation of the results of treatment was carried out after 6 injections of reslizumab at a dose of 3 mg/kg 1 time every 4 weeks. The obtained data were processed by means of the “Statistica 12.0” program (StatSoft, USA). The differences in the indicators were considered statistically significant at p < 0.05. RESULTS: After 6 injections of reslizumab both a noticeable improvement in asthma control and a decrease in the severity of the nasal symptoms were noted. A more evident effect in diminution of asthma symptoms due to the use of reslizumab was obtained in patients with severe eosinophilic asthma with CRSwNP compared with cases without polyps. CONCLUSION: Treatment with reslizumab in patients with eosinophilic asthma and concomitant CRS with polyps and eosinophilic CRS leads not only to improved control of asthma symptoms but also to significant regression of nasal symptoms.

show abstract

Novel therapeutic approaches targeting endotypes of severe airway disease

Cited by 9 publications

References 170 publications

Age-Associated Changes of Nasal Bacterial Microbiome in Patients With Chronic Rhinosinusitis

Age-Associated Changes of Nasal Bacterial Microbiome in Patients With Chronic Rhinosinusitis

Omalizumab and allergen immunotherapy for respiratory allergies

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Contact Info

Product

Resources

About